Compare Diamondback Energy Inc (FANG) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs 10X Genomics Inc — how do they compare? Diamondback Energy Inc trades at $192.03 (market cap $53.67B), while 10X Genomics Inc trades at $81 (market cap $10.07B). The key difference: Diamondback Energy Inc is far larger — about 5.3× 10X Genomics Inc's market cap, and Diamondback Energy Inc pays a 2.3% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and 10X Genomics Inc for 91 Days on average.
| FANG | TXG | |
|---|---|---|
Market Cap | $53.67B | $10.07B |
Volume | 2,250,644 | 5,657,286 |
Sector | Energy | Health |
52-Week High | $213.69 | $97.74 |
52-Week Low | $137.29 | $11.48 |
Typical Hold Time | 69 Days | 91 Days |
Enterprise Value | $65.83B | $9.59B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $192.13, up 4.2% in the last session, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains solid cash flow from operations. Revenue growth is robust, with 2025 revenue reaching $14.93 billion, though net income margins have compressed. A dividend of $1.10 is scheduled for August 2026, and institutional interest remains high.
The outlook is positive with a consensus price target of $231.77, implying 20% upside. Risks include volatile oil prices and insider selling, but strong Permian Basin positioning and efficient operations support growth. Earnings on November 2, 2026, will be critical for near-term momentum.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
